Mereo BioPharma (MREO) Equity Ratio (2017 - 2026)

Mereo BioPharma (MREO) has 7 years of Equity Ratio data on file, last reported at 0.84 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.84, down 4.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.84 (down 4.65% YoY), and the FY2025 annual result was 0.89, up 11.65% from the prior year.
• Equity Ratio declined to 0.84 in Q1 2026 per MREO's latest filing, from 0.89 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.89 in Q4 2025 and troughed at 0.82 in Q3 2024.
• A 5-year average of 0.65 and a median of 0.82 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2025 and 2026: Equity Ratio soared 206.36% in 2025, then dropped 4.65% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.5 in 2022, then jumped by 52.74% to 0.76 in 2023, then grew by 5.02% to 0.8 in 2024, then climbed by 11.65% to 0.89 in 2025, then decreased by 5.9% to 0.84 in 2026.
• Business Quant data shows MREO's Equity Ratio at 0.84 in Q1 2026, 0.89 in Q4 2025, and 0.87 in Q3 2025.